LEXX
Price
$0.87
Change
+$0.02 (+2.35%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
16.61M
18 days until earnings call
STRO
Price
$0.71
Change
-$0.02 (-2.74%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
61.99M
38 days until earnings call
Interact to see
Advertisement

LEXX vs STRO

Header iconLEXX vs STRO Comparison
Open Charts LEXX vs STROBanner chart's image
Lexaria Bioscience
Price$0.87
Change+$0.02 (+2.35%)
Volume$281
Capitalization16.61M
Sutro Biopharma
Price$0.71
Change-$0.02 (-2.74%)
Volume$5.63K
Capitalization61.99M
LEXX vs STRO Comparison Chart in %
Loading...
LEXX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LEXX vs. STRO commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LEXX is a Buy and STRO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (LEXX: $0.85 vs. STRO: $0.73)
Brand notoriety: LEXX and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LEXX: 49% vs. STRO: 739%
Market capitalization -- LEXX: $16.96M vs. STRO: $60.37M
LEXX [@Biotechnology] is valued at $16.96M. STRO’s [@Biotechnology] market capitalization is $60.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LEXX’s FA Score shows that 0 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • LEXX’s FA Score: 0 green, 5 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both LEXX and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LEXX’s TA Score shows that 4 TA indicator(s) are bullish while STRO’s TA Score has 3 bullish TA indicator(s).

  • LEXX’s TA Score: 4 bullish, 4 bearish.
  • STRO’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, LEXX is a better buy in the short-term than STRO.

Price Growth

LEXX (@Biotechnology) experienced а -11.56% price change this week, while STRO (@Biotechnology) price change was -7.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +32.93%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

LEXX is expected to report earnings on Jul 18, 2025.

STRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STRO($62M) has a higher market cap than LEXX($16.6M). LEXX (-59.571) and STRO (-60.109) have similar YTD gains . LEXX has higher annual earnings (EBITDA): -9.32M vs. STRO (-203.18M). STRO has more cash in the bank: 249M vs. LEXX (6.54M). LEXX has less debt than STRO: LEXX (124K) vs STRO (21.4M). STRO has higher revenues than LEXX: STRO (66.4M) vs LEXX (526K).
LEXXSTROLEXX / STRO
Capitalization16.6M62M27%
EBITDA-9.32M-203.18M5%
Gain YTD-59.571-60.10999%
P/E RatioN/AN/A-
Revenue526K66.4M1%
Total Cash6.54M249M3%
Total Debt124K21.4M1%
FUNDAMENTALS RATINGS
LEXX vs STRO: Fundamental Ratings
LEXX
STRO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9592
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (27) in the Pharmaceuticals Major industry is in the same range as LEXX (37) in the null industry. This means that STRO’s stock grew similarly to LEXX’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LEXX (100) in the null industry. This means that STRO’s stock grew similarly to LEXX’s over the last 12 months.

LEXX's SMR Rating (99) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that LEXX’s stock grew similarly to STRO’s over the last 12 months.

STRO's Price Growth Rating (92) in the Pharmaceuticals Major industry is in the same range as LEXX (95) in the null industry. This means that STRO’s stock grew similarly to LEXX’s over the last 12 months.

STRO's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as LEXX (100) in the null industry. This means that STRO’s stock grew similarly to LEXX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LEXXSTRO
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 21 days ago
87%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
LEXX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AVBP22.910.10
+0.44%
ArriVent BioPharma
NTR58.120.07
+0.12%
Nutrien Ltd
ELDN2.69-0.05
-1.82%
Eledon Pharmaceuticals
AUST1.27-0.03
-2.25%
Austin Gold Corp
AAPG39.60-1.21
-2.96%
Ascentage Pharma Group

LEXX and

Correlation & Price change

A.I.dvisor tells us that LEXX and PDSB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LEXX and PDSB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LEXX
1D Price
Change %
LEXX100%
-1.23%
PDSB - LEXX
29%
Poorly correlated
-2.76%
OCUL - LEXX
28%
Poorly correlated
-2.54%
CRBU - LEXX
28%
Poorly correlated
-6.67%
ERAS - LEXX
27%
Poorly correlated
N/A
STRO - LEXX
27%
Poorly correlated
-8.14%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with TRDA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
-8.14%
TRDA - STRO
41%
Loosely correlated
-1.57%
ATXS - STRO
40%
Loosely correlated
N/A
DNLI - STRO
39%
Loosely correlated
-2.69%
TCRX - STRO
39%
Loosely correlated
-5.41%
PDSB - STRO
39%
Loosely correlated
-2.76%
More